You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In a reader survey, researchers and core lab staff share how they think cores are doing.
PathoNext will run Agendia's assays in its labs using next-generation sequencing and work with HiSS, Agendia's German distributor, to offer the tests to German patients.
Recently presented data confirm prior findings that Agendia's MammaPrint may help doctors decide whether to limit tamoxifen treatment in certain patients.
The San Diego-based genomic analysis firm said the decline in revenues was due to the impact of the COVID-19 pandemic on research customers.
The investment bank said the company's molecular diagnostics have the potential to replace microarrays for cytogenetics analysis.
A retrospective cohort study uncovered microRNA signatures that could tell lung cancer patients apart from others, including patients with other, non-tumor lung conditions.
The federal court order dismissed the case with prejudice, which prevents the plaintiffs from raising the case again.
The investment banking firm has lowered its rating for shares of the sequencing giant, but raised its price target to $340 from $330.
Tempus said that Akesogen's lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and more.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.
Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.
A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.
In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.